acceleratediagnostics.com - AXDX Company Short-Term Debt

Accelerate Diagnostics, Inc. (AXDX) - corporate logo

Accelerate Diagnostics (AXDX) is facing a liquidity shortage due to the slow market rollout of diagnostic products, forcing the company to restructure its loans. Meanwhile, the business model generates revenue from the demand for rapid sepsis tests and the expansion of the Pheno systems network. The price trend with the 0.00 indicator clearly demonstrates the debt dynamics. The firm's developments promote sustainable medicine by reducing wasted resources through precise microbiological diagnostics.

AXDX (Accelerate Diagnostics, Inc.) Company Short-Term Debts history from 07/04/2022 to 05/24/2025

Accelerate Diagnostics Inc - analytical breakdowns and key metrics (AXDX)

- price and consensus price forecast:
Stock Price Accelerate Diagnostics, Inc.|AXDX - Analyst Consensus Forecast
- market capitalization data:
Market Value Accelerate Diagnostics, Inc.|AXDX - Business Value
- book capitalization data:
Book Value per Share Accelerate Diagnostics|AXDX - Book Capitalization|Market Value to Book Value Ratio acceleratediagnostics.com|AXDX - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Accelerate Diagnostics|AXDX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Accelerate Diagnostics|AXDX - Company Total Debt Obligations|Debts to Book Capitalization Accelerate Diagnostics, Inc.|AXDX - Long-Term Debt Volume|Company Short-Term Debt Accelerate Diagnostics
Analysis of all company metrics:Accelerate Diagnostics, Inc. AXDX
Finished products of Accelerate Diagnostics

This indicator measures the repayment speed of obligations with a maturity of up to one year, allowing for a comparison of accounts payable dynamics with operating cash flow to assess liquidity. By analyzing current financial debt, an investor can determine how effectively Jack Phillips' strategy to expand the commercial base of Accelerate Diagnostics (AXDX) is transforming into actual solvency amid the modernization of hospital testing standards.

Competitor analysis for Accelerate Diagnostics

Agilent - Company Short-Term Debts|DGX: Company Short-Term Debts|Company Short-Term Debt Illumina Corp|Exact Sciences Inc. (EXAS) - Company Short-Term Indebtedness|RVTY (Revvity, Inc.) - Company Short-Term Debts|Company Short-Term Debts BIO|Company Short-Term Debt Anbio (NNNN)|Company Short-Term Debt Sotera Health Corp SHC|QDEL: Company Current Liabilities|OPKO Health Corp. - Short-Term Debt|Company Short-Term Debt CDNA (CareDx, Inc.)|MRVI - Short-Term Debt Volume|Fulgent Genetics - Company Short-Term Debts|LAB (Standard BioTools Inc) - Short-Term Debt Volume|CTKB: Company Short-Term Debt|Short-Term Debt Volume OraSure Corp|Company Short-Term Debts XGN|Company Short-Term Debts mdxhealth.com (MDXH)|Lucid Diagnostics - Company Short-Term Debts|Company Current Liabilities Prenetics Global Limited PRE|IMDX: Company Short-Term Debts|TRIB - Company Current Liabilities|Company Short-Term Debts PRPH|AIMD (ainos.com) - Short-Term Debt|Company Short-Term Debt Co-Diagnostics|Company Short-Term Debt Heart Test Laboratories, Inc.|Biomerica, Inc - Company Short-Term Debts|Short-Term Debt CDIO (cardiodiagnosticsinc.com)|Company Short-Term Debt Virax Biolabs Group|Company Short-Term Loans and Borrowings bluejaydx.com BJDX|Aspira Women's Health Inc. - Company Short-Term Debts|CENTOGENE N.V. (CNTG) - Company Short-Term Debts|ENZ - Company Current Liabilities|Fresh2 Group (FRES) - Amount of Current Liabilities|Company Short-Term Debts GENE (Genetic Technologies Ltd)|Short-Term Debt 23andme.com (ME)|Psychemedics Corporation (PMD) - Company Current Liabilities